Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Bayer

Status: Completed

Conditions: Abscess, Intra-Abdominal; Secondary Peritonitis

Treatments: Drug: Moxifloxacin (Avelox, BAY12-8039)

Study type: Observational

Funder types: Industry

Identifiers

NCT01096511

AX0910CN (Other Identifier)

14537

Details and patient eligibility

About

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is to define the types of cIAI infections that require Moxifloxacin i.v. therapy in China.

Enrollment: 1,001 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin infusion with/without sequential tablet treatment can be included into the study. The local Moxifloxacin product information must be considered.

Exclusion criteria

• Contraindications stated in the local Moxifloxacin product information. Warnings and precautions, stated in the local Moxifloxacin product information must be considered as potential exclusion criteria.

Trial design

1,001 participants in 1 patient group

Group 1

Treatment:

Drug: Moxifloxacin (Avelox, BAY12-8039)